Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Epetirimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.60 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.60 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.35 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epetirimod SCHEMBL4985288 | 0.99 | TLR7 (0.61) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Epetirimod SCHEMBL4178322 | 0.96 | TLR7 (0.60) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Epetirimod SCHEMBL4178900 | 0.94 | TLR7 (0.61) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Epetirimod SCHEMBL29454521 | 0.91 | TLR7 (0.70) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Epetirimod SCHEMBL29350668 | 0.91 | TLR7 (0.70) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Epetirimod SCHEMBL544542 | 0.91 | TLR7 (0.70) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Imiquimod SCHEMBL9602249 | 0.86 | TLR7 (0.82) | TLR7PDE4DHTR2AHTR2BLMNA | |
| Water SCHEMBL5343392 | 0.83 | TLR7 (0.43) | TLR7PDE4DHTR2AHTR2BLMNA | |
| SCHEMBL5375816 | 0.81 | TLR7 (0.44) | TLR7PDE4DHTR2AHTR2BLMNA | |
| SCHEMBL5505243 | 0.79 | TLR7 (0.55) | TLR7PDE4DHTR2AHTR2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188513-A1 | 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate | TAKED PHARMACEUTICAL COMPANY LIMITED | 2008-08-07 | — | — | US | disclosed |
| EP-1833479-A2 | 1-(2-METHYLPROPYL)-1H-IMIDAZO 4,5-C(1,5 )NAPHTHYRIDIN-4-AMINE ETHANESULFONATE AND 1-(2-METHYLPROPYL)-1H-IMIDAZOÝ4,5-C 1,5 NAPHTHYRIDIN-4-AMINE METHANESULFONATE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006073939-A2 | 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE ETHANESULFONATE AND 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE METHANESULFONATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188513-A1 | 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NDC1, CLIC1 | HTR2A 272/4885ADRA1D 440/4885ADRA1A 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.